Mike Kagey

Company: Leap Therapeutics

Job title: Vice President, Translational Medicine

Seminars:

Tumoral DKK1 Expression as a Predictor of Clinical Benefit to DKN-01 11:30 am

DKK1 is overexpressed in many cancers, often leading to worse outcomes by promoting tumor growth, metastasis and contributing to an immunosuppressive tumor microenvironment DKN-01 in combination with standard of care therapies has demonstrated compelling clinical data with enhanced activity seen in DKK1-high patients DKK1 RNAscope CDx development to support the clinical development of DKN-01 is…Read more

day: Day 1 Track B AM